CR6834A - Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo - Google Patents

Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo

Info

Publication number
CR6834A
CR6834A CR6834A CR6834A CR6834A CR 6834 A CR6834 A CR 6834A CR 6834 A CR6834 A CR 6834A CR 6834 A CR6834 A CR 6834A CR 6834 A CR6834 A CR 6834A
Authority
CR
Costa Rica
Prior art keywords
complexes
compositions
same
drugs containing
macromolecular drugs
Prior art date
Application number
CR6834A
Other languages
English (en)
Original Assignee
Trustess Of The University Of Illinois Board Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustess Of The University Of Illinois Board Of filed Critical Trustess Of The University Of Illinois Board Of
Publication of CR6834A publication Critical patent/CR6834A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Los compuestos, particularmente las microemulsiones que poseen complejos macroleculares, son administradas a los individuos que sufren de una enfermedad o condicion y los complejos descargan la droga in vivo, para tratar la enfermedad o condicion y para reducir, revertir o eliminar las complicaciones que son asociadas con la enfermedad.
CR6834A 2000-06-08 2002-11-27 Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo CR6834A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/589,721 US6417237B1 (en) 2000-06-08 2000-06-08 Macromolecular drug complexes and compositions containing the same

Publications (1)

Publication Number Publication Date
CR6834A true CR6834A (es) 2004-03-03

Family

ID=24359207

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6834A CR6834A (es) 2000-06-08 2002-11-27 Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo

Country Status (12)

Country Link
US (1) US6417237B1 (es)
EP (1) EP1286659A2 (es)
JP (1) JP2003535149A (es)
CN (1) CN1441666A (es)
AU (1) AU2001263277A1 (es)
BR (1) BR0111506A (es)
CA (1) CA2409268A1 (es)
CR (1) CR6834A (es)
IL (1) IL152978A0 (es)
MX (1) MXPA02012064A (es)
WO (1) WO2001093911A2 (es)
ZA (1) ZA200209229B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60321572D1 (de) * 2002-06-20 2008-07-24 Amnon Sintov Transdermales arzneimittelverabreichungssystem
ZA200505306B (en) * 2002-12-31 2006-09-27 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers
EP2460530A3 (en) * 2002-12-31 2012-08-29 Althea Technologies, Inc. Human growth hormone crystals and methods for preparing them
JP2007502841A (ja) * 2003-08-20 2007-02-15 ニューレン ファーマシューティカルズ リミテッド 成長ホルモンの２０ｋＤａ胎盤性変種を用いる体形成療法
US7736653B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier
US20050147581A1 (en) * 2003-11-19 2005-07-07 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes having improved stability and therapeutic use of the same
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP1797870A1 (en) * 2005-12-14 2007-06-20 The Jordanian Pharmaceutical Manufacturing Co. Oral delivery of protein drugs using microemulsion
EP1976551A4 (en) * 2005-12-23 2009-12-30 Altus Pharmaceuticals Inc COMPOSITIONS COMPRISING COMPLEX PROTEIN CRYSTALS BY POLYCATIONS AND PROCESSING METHOD THEREOF
CN103140216B (zh) 2010-09-03 2015-07-15 参天股份公司 用于治疗眼睛疾病的油包水型乳液
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
EP2425814B1 (en) * 2010-09-03 2013-06-19 Novagali Pharma S.A. A water-in-oil type emulsion for treating a disease of the eye
WO2013101749A1 (en) * 2011-12-29 2013-07-04 Latitude Pharmaceuticals, Inc. Stabilized glucagon nanoemulsions
EP3043810B1 (en) 2013-09-09 2019-10-23 CanImGuide Therapeutics AB Immune system modulators
US10034834B1 (en) * 2014-10-24 2018-07-31 Aqua Regenerative Therapies Llc Compositions and methods for treating skin conditions
WO2016069409A1 (en) 2014-10-27 2016-05-06 Latitude Pharmaceuticals, Inc. Parenteral glucagon formulations
DK3265117T3 (da) 2015-03-06 2021-02-08 Canimguide Therapeutics Ab Immunsystemmodulatorer og præparater

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE636812A (es) * 1958-10-06
US4003792A (en) 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US3577534A (en) 1968-06-20 1971-05-04 Canada Packers Ltd Stable orally active heparinoid complexes
WO1983000150A1 (en) * 1981-07-02 1983-01-20 Walton, Alan, G. Glycosaminoglycan drug complexes
US4585754A (en) 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
US5008109A (en) 1984-05-25 1991-04-16 Vestar, Inc. Vesicle stabilization
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
KR930001305B1 (ko) * 1989-10-19 1993-02-25 니뽕 유우시 가부시끼가이샤 당 응답형 고분자 복합체(Polymer Complexes of Sugar Response Type)
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
EP0794796A1 (en) 1994-12-22 1997-09-17 Access Pharmaceuticals, Inc. Complexes of dermatan sulfate and drugs, giving improved pharmacokinetics
WO1997037680A1 (en) 1996-04-05 1997-10-16 The Board Of Trustees Of The University Of Illinois Macromolecular complexes for drug delivery

Also Published As

Publication number Publication date
JP2003535149A (ja) 2003-11-25
WO2001093911A3 (en) 2002-03-07
BR0111506A (pt) 2003-06-24
EP1286659A2 (en) 2003-03-05
AU2001263277A1 (en) 2001-12-17
IL152978A0 (en) 2003-06-24
CN1441666A (zh) 2003-09-10
MXPA02012064A (es) 2004-08-19
ZA200209229B (en) 2003-08-07
CA2409268A1 (en) 2001-12-13
WO2001093911A2 (en) 2001-12-13
US6417237B1 (en) 2002-07-09

Similar Documents

Publication Publication Date Title
CR6834A (es) Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
BR0015188A (pt) Composições farmacêuticas
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
ES2080307T3 (es) Composiciones farmaceuticas.
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
FI956014A (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
AR033548A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa, un procedimiento para su preparacion, equipo transportable a modo de ''kit'', el uso de dicha composicion en la fabricacion de medicamentos, un inhibidor de lipasa y un secuestrante de acidos biliares
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
AR029763A1 (es) Uso de una combinacion de una nsaid y un inhibidor de quinasa egfr para la manufactura de un medicamento para el tratamiento o inhibicion de polipos colonicos y cancer colorectal, composicion farmaceutica y medicamento
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
RS52651B (en) PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENS AND / OR ESTROGENS AND 5-METHYL- (6S) -TETRAHYDROPHOLATE
AR028959A1 (es) Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares
ES2195638T3 (es) Preparaciones de combinaciones farmaceuticas en forma solida de dosificacion que contienen cardevilol e hidroclorotiazida.
BR0014312B1 (pt) composição farmacêutica contendo uma combinação farmacêutica compreendendo loteprednol e azelastina, medicamento e seu processo de produção, e uso da referida combinação.
HK1068606A1 (en) Novel aminobenzoephenones
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
RS52011B (sr) Nova primena derivata taksoida
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
ES2323864T3 (es) Uso de complejos de ginkgo para la potenciacion de las funciones cognitivas y alivio de la fatiga mental.
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion

Legal Events

Date Code Title Description
FC90 Application suspended